Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study
作者
Claire N. Harrison,Nicolaas PM Schaap,Alessandro Maria Vannucchi,Jean‐Jacques Kiladjian,Éric Jourdan,Richard T. Silver,Harry C. Schouten,Francesco Passamonti,Sonja Zweegman,Moshe Talpaz,Srđan Verstovšek,Torsten G. Gerike,Shelonitda Rose,Mingyu Li,Tymara Berry,Carrie M. Brownstein,Ruben A. Mesa